AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9709140
Drug: Vecuronium bromide
RxNorm normalized name: Vecuronium Bromide
DrugBank: Vecuronium (DB01339)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vecuronium bromide 0.25 ml (0.5 mg)
Trial: 9709140
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline 0.25 ml
Trial: 8574271
Drug: Oral oxandrolone
RxNorm normalized name: Oxandrolone
DrugBank: Oxandrolone (DB00621)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral oxandrolone (ASOX)
Trial: 8574271
Drug: Parenteral nandrolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nandrolone decanoate (ASND)
Trial: 31272550
Drug: Rituximab 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab 1,000 mg intravenous on days 0 and 12 post-transplant
Trial: 28948482
Drug: Single 90-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 90-mg dose of hydrocodone ER under fed conditions
Trial: 28948482
Drug: Single 90-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 90-mg dose of hydrocodone ER under fasted conditions
Trial: 28948482
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of hydrocodone ER (45 mg twice daily on days 2-3, 60 mg twice daily on days 4-5, 90 mg twice daily on days 6-10, and 90 mg once in the morning on day 11) under fed conditions
Trial: 28948482
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of hydrocodone ER under fasted conditions
Trial: 21661100
Drug: Aspart insulin
RxNorm normalized name: Aspart Insulin
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aspart insulin protocol every 2 hours when BG > 200 mg/dL, and if admitted, began daily detemir in the ED
Trial: 21661100
Drug: Aspart insulin
RxNorm normalized name: Aspart Insulin
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aspart insulin protocol
Trial: 11087767
Drug: Haloperidol (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (mean dose, 1.8 mg/d)
Trial: 11087767
Drug: Trazodone (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazodone (mean dose, 200 mg/d)
Trial: 7084867
Drug: Irradiation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irradiation therapy combined with vitamin A palmitate (1.5 mill. I.U./day; total dose: 30 mill. I.U.), applied orally
Trial: 30204741
Drug: Topical decolonization
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical decolonization with nasal mupirocin and chlorhexidine body wash
Trial: 26967008
Drug: Oral fluid
RxNorm normalized name: cascara sagrada ORAL FLUID EXTRACT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral fluid intake after tonsillectomy (mean 18.2 mL/kg, SD 10.8 mL/kg)
Trial: 22794154
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of clozapine (100 mg)
Trial: 22794154
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of clozapine (100 mg)
Trial: 22794154
Drug: Both test
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both test and reference formulations of clozapine
Trial: 11886002
Drug: Treosulfan 7
RxNorm normalized name: TREOSULFAN
DrugBank: Treosulfan (DB11678)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Treosulfan 7 g/m2 infused over 30 min, repeated every 4 weeks
Trial: 11886002
Drug: Leuprorelin 3.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprorelin 3.75 mg injected subcutaneously or intramuscularly, repeated every 4 weeks
Trial: 10082251
Drug: Antiepilepsirine (AES)
RxNorm normalized name: Ae-turmeric
DrugBank: Ilepcimide (DB16942)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiepilepsirine (AES) 10 mg/kg per day
Trial: 6349650
Drug: Meclofenamate sodium
RxNorm normalized name: Meclofenamate Sodium
DrugBank: Meclofenamic acid (DB00939)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meclofenamate sodium (300 mg per day for a maximum of 3 weeks)
Trial: 6349650
Drug: Indomethacin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (150 mg per day)
Trial: 10567956
Drug: Basiliximab (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basiliximab (20 mg injections, one prior to surgery and one on Day 4 posttransplant)
Trial: 8671319
Drug: 75 microgram
RxNorm normalized name: Norgestrel 75 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 microgram dose of desogestrel
Trial: 8671319
Drug: 30 microgram
RxNorm normalized name: Levonorgestrel 30 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 microgram dose of desogestrel
Trial: 8671319
Drug: 50 microgram
RxNorm normalized name: Digoxin 250 microgram oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 microgram dose of desogestrel
Trial: 1751794
Drug: Epoetin (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epoetin (all doses combined)
Trial: 6753888
Drug: Oral disopyramide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral disopyramide phosphate (loading dose of 150, 200, or 300 mg followed by maintenance doses of 100, 150, or 200 mg every 6 hours based on weight)
Trial: 27844152
Drug: Clinician-directed therapy
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinician-directed therapy (n = 26)
Trial: 27844152
Drug: SwallowIT-assisted therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SwallowIT-assisted therapy (n = 26)
Trial: 27844152
Drug: Patient-directed therapy
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-directed therapy (n = 27)
Trial: 24593317
Drug: Alcohol-free essential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcohol-free essential oil mouthwash (AF-EOMW) used twice a day
Trial: 21380536
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser treatment (630-670 nm, 1.875 J/cm²) plus scaling and root planing (SRP) for five consecutive days
Trial: 21380536
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser treatment (630-670 nm, 1.875 J/cm²) plus scaling and root planing (SRP) for ten consecutive days
Trial: 19056656
Drug: Spread with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spread with plant sterol esters (1.1 g/d or 2.2 g/d plant sterols; n = 120)
Trial: 17888974
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (mitral surgery alone or medical therapy)
Trial: 15002024
Drug: Timolol 0.5%
RxNorm normalized name: Timolol 0.5% Ophthalmic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol 0.5% twice daily (0800 and 2000 hours)
Trial: 8011964
Drug: Caplet formulation
RxNorm normalized name: Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caplet formulation (product A)
Trial: 8011964
Drug: Tablet formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet formulation (product B)
Trial: 28800765
Drug: Flurbiprofen axetil
RxNorm normalized name: Flurbiprofen axetil
DrugBank: Flurbiprofen axetil (DB14938)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen axetil administered preoperatively (n=16)
Trial: 28800765
Drug: Flurbiprofen axetil
RxNorm normalized name: Flurbiprofen axetil
DrugBank: Flurbiprofen axetil (DB14938)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen axetil administered post-MTS (n=14)
Trial: 22397878
Drug: High-CHO/low-GI diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-CHO/low-GI diet (L)
Trial: 12538184
Drug: Sodium chloride
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium chloride solution dorsal penile block
Trial: 8803517
Drug: FK-224 (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FK-224 (2 mg)
Trial: 1611544
Drug: tyrosine-adsorbed Dermatophagoides
RxNorm normalized name: Tyrosine
DrugBank: Tyrosine (DB00135)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tyrosine-adsorbed Dermatophagoides pteronyssinus vaccine
Trial: 29258367
Drug: Simvastatin 20
RxNorm normalized name: simvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg daily for 6 months
Trial: 25130052
Drug: Oxymorphone (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxymorphone (10, 20, and 40 mg)
Trial: 25130052
Drug: Oxymorphone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxymorphone (40 mg)
Trial: 25130052
Drug: Oxycodone (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone (10, 20, and 40 mg)
Trial: 24800725
Drug: Pasireotide LAR
RxNorm normalized name: pasireotide LAR 20 MG Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pasireotide LAR 20 mg/month
Trial: 24800725
Drug: Pasireotide LAR
RxNorm normalized name: pasireotide LAR 20 MG Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pasireotide LAR 40 mg/month
Trial: 24800725
Drug: Pasireotide LAR
RxNorm normalized name: pasireotide LAR 20 MG Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pasireotide LAR 60 mg/month
Trial: 10699346
Drug: Pseudomonas aeruginosa
RxNorm normalized name: Pseudomonas aeruginosa
DrugBank: Pseudomonas aeruginosa (DB19284)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pseudomonas aeruginosa OMPs vaccine
Trial: 9356538
Drug: Medium-protein diet
RxNorm normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-protein diet (1.0 g/kg)
Trial: 3780124
Drug: Diazepam (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (0.15 and 0.30 mg/kg)
Trial: 1294894
Drug: Buspirone (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone (15 mg)
Trial: 3780124
Drug: Buspirone +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone + Diazepam (0.30 mg/kg)
Trial: 3936091
Drug: Diazepam (0.30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (0.30 mg/kg)
Trial: 25266547
Drug: Aripiprazole lauroxil
RxNorm normalized name: Aripiprazole lauroxil
DrugBank: Aripiprazole lauroxil (DB14185)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aripiprazole lauroxil 441 mg IM in the deltoid
Trial: 25266547
Drug: Aripiprazole lauroxil
RxNorm normalized name: Aripiprazole lauroxil
DrugBank: Aripiprazole lauroxil (DB14185)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aripiprazole lauroxil 441 mg IM in the gluteal
Trial: 25266547
Drug: Aripiprazole lauroxil
RxNorm normalized name: Aripiprazole lauroxil
DrugBank: Aripiprazole lauroxil (DB14185)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aripiprazole lauroxil 441 mg IM in the deltoid or gluteal
Trial: 22382362
Drug: Ipilimumab 3
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab 3 or 10 mg/kg every 3 weeks for four doses followed by maintenance dosing
Trial: 28422751
Drug: Ipilimumab treatment
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab treatment
Trial: 20067654
Drug: Surgical or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical or catheter interventional treatment of coarctation
Trial: 18837100
Drug: Purgative preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purgative preparation
Trial: 16428147
Drug: Silicic acid
RxNorm normalized name: silicic acid
DrugBank: Silicic acid (DB14138)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicic acid applied twice daily for 8 weeks
Trial: 10229307
Drug: 75 g
RxNorm normalized name: Zosyn 3.375 GM Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 g oral glucose tolerance test (OGTT)
Trial: 8902442
Drug: 3 mg/day
RxNorm normalized name: Neupro 3 MG/Day 24 HR Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg/day E2 cream continuously for 12 months
Trial: 1906893
Drug: Oral estradiol
RxNorm normalized name: estradiol Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral estradiol administration
Trial: 1906893
Drug: Transdermal estradiol
RxNorm normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal estradiol administration
Trial: 1906893
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (oral and transdermal)
Trial: 11575229
Drug: Valsartan 80
RxNorm normalized name: valsartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 80 mg + Hydrochlorothiazide 12.5 mg (V+H)
Trial: 8988832
Drug: Flurbiprofen 1
RxNorm normalized name: flurbiprofen 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen 1 mg.kg-1
Trial: 8988832
Drug: Flurbiprofen 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen 0.5 mg.kg-1
Trial: 2891316
Drug: Topical levocabastine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical levocabastine (ocular)
Trial: 2891316
Drug: Topical levocabastine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical levocabastine (nasal)
Trial: 2891316
Drug: Topical levocabastine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical levocabastine (nasal and ocular)
Trial: 30236511
Drug: Pazopanib (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pazopanib (800 mg orally daily for 24 weeks)
Trial: 26966279
Drug: Anacetrapib (ANA)
RxNorm normalized name: Ana-Lex
DrugBank: Anacetrapib (DB06630)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anacetrapib (ANA) 100 mg/d
Trial: 12833113
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg sibutramine for 14 days
Trial: 12833113
Drug: 10 months
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 months open treatment with 15 mg sibutramine and dietary advice
Trial: 9798779
Drug: Early postoperative
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early postoperative intraperitoneal chemotherapy (EPIC) with mitomycin C on postoperative day 1 and 5-fluorouracil on postoperative days 2 to 5
Trial: 28119434
Drug: Early group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early group (intravenous edaravone [30 mg] started before or during tPA)
Trial: 22321227
Drug: High hs-CRP
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High hs-CRP group (hs-CRP ≥ 3 mg/L)
Trial: 22321227
Drug: Moderate hs-CRP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate hs-CRP group (hs-CRP 1-3 mg/L)
Trial: 22321227
Drug: Normal hs-CRP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal hs-CRP group (hs-CRP < 1 mg/L)
Trial: 22321227
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose atorvastatin (20 mg)
Trial: 22321227
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose atorvastatin (40 mg)
Trial: 19382480
Drug: Maren Zipi
RxNorm normalized name: 3-carene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maren Zipi pill (Control)
Trial: 11412155
Drug: Nefopam 0.12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nefopam 0.12 mg.kg‐1
Trial: 2842144
Drug: Flumazenil (3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flumazenil (3.0 mg)
Trial: 3543247
Drug: Subcutaneous (SC)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (SC) recombinant interferon (IFN) alfa‐2b at a dosage of 2 X 10(6) IU/m2 three times weekly.
Trial: 3543247
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) recombinant interferon (IFN) alfa‐2b at a dosage of 30 X 10(6) IU/m2 for five consecutive days every 3 weeks.
Trial: 3543247
Drug: Subgroup analysis
RxNorm normalized name: RSV subgroup A stabilized prefusion F protein
DrugBank: Recombinant stabilized RSV A prefusion F antigen (DB18713)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subgroup analysis of patients with prior nephrectomy, no prior treatment, and lack of bone metastases.
Trial: 3543247
Drug: Both SC
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both SC and IV routes of administration.
Trial: 24114306
Drug: Delayed antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed antibiotics group
Trial: 22097104
Drug: Assertiveness Music
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Assertiveness Music Therapy
Trial: 15473523
Drug: Iron supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron supplementation (2 mg/kg/day)
Trial: 19032560
Drug: Ropivacaine 5
RxNorm normalized name: fentanyl-ropivacaine 5 mcg/mL-0.1%-0.9% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 5 mg/ml
Trial: 9496328
Drug: Intravenous (i.v.)
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (i.v.) administration of 10,000 IU recombinant human LH
Trial: 9496328
Drug: Intramuscular (i.m.)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (i.m.) administration of 10,000 IU recombinant human LH
Trial: 9496328
Drug: Subcutaneous (s.c.)
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous (s.c.) administration of 10,000 IU recombinant human LH
Trial: 7993988
Drug: Enteric-coated tablet
RxNorm normalized name: Walgreens Low Dose Aspirin 81mg Enteric-Coated Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enteric-coated tablet (EC)
Trial: 7993988
Drug: Plain capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain capsule (PC)
Trial: 2789363
Drug: Ponsinomycin 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ponsinomycin 400 mg
Trial: 2789363
Drug: Ponsinomycin 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ponsinomycin 800 mg
Trial: 2789363
Drug: Ponsinomycin 1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ponsinomycin 1200 mg
Trial: 29127558
Drug: Perineural dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Perineural dexamethasone (4 mg)
Trial: 29127558
Drug: Perineural dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Perineural dexamethasone (4 mg) vs Intravenous dexamethasone (4 mg)
Trial: 29127558
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg vs 4 mg dexamethasone
Trial: 28259777
Drug: Tenofovir alafenamide
RxNorm normalized name: Tenofovir Alafenamide
DrugBank: Tenofovir alafenamide (DB09299)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tenofovir alafenamide (25 mg), rilpivirine (25 mg), emtricitabine (200 mg)
Trial: 28259777
Drug: Tenofovir disoproxil
RxNorm normalized name: Tenofovir Disoproxil
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tenofovir disoproxil fumarate (300 mg), rilpivirine (25 mg), emtricitabine (200 mg)
Trial: 26497961
Drug: No rate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No rate control drug (baseline)
Trial: 17323614
Drug: Atorvastatin 20
RxNorm normalized name: atorvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20 mg or Simvastatin 40 mg
Trial: 17323614
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of statin + 200 mg micronized fenofibrate
Trial: 17323614
Drug: Statin +
RxNorm normalized name: Nystatin
DrugBank: Nystatin (DB00646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Statin + 3.6 g n-3 polyene fatty acids (PUFA n-3)
Trial: 14664413
Drug: Climex (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Climex (5 chewable tablets daily between meals)
Trial: 10760307
Drug: High-dose chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose chemotherapy plus hematopoietic stem cells
Trial: 8622391
Drug: Fluoxetine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (20 mg once daily)
Trial: 29720370
Drug: Low serum
RxNorm normalized name: ZINC OXIDE 20 g in 100 mL TOPICAL CREAM [Sunceutical SPF 50 Mineral Glow Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low serum 25(OH)D concentrations (<25 nmol/L)
Trial: 27454372
Drug: Higher intercepts
RxNorm normalized name: INTERCEPTOR
DrugBank: Milbemycin oxime (DB11531)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher intercepts during treatment
Trial: 11731725
Drug: Electroconvulsive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Electroconvulsive therapy (ECT) with bilateral electrode placement at 50% above the titrated seizure threshold
Trial: 9142008
Drug: AS-013 (prostaglandin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS-013 (prostaglandin E1 prodrug) administered by intravenous injection 5 d/wk for 4 weeks
Trial: 7956270
Drug: Both sequences
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both sequences of surgical treatments
Trial: 3230146
Drug: A-56234 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A-56234 at 20 mg